Business Description
Vaxart Inc
NAICS : 325414
SIC : 2836
ISIN : US92243A2006
Description
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.23 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 0.27 | |||||
| Debt-to-EBITDA | -0.3 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -4.4 | |||||
| Beneish M-Score | 19.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.5 | |||||
| 3-Year EBITDA Growth Rate | -17.1 | |||||
| 3-Year EPS without NRI Growth Rate | -15.8 | |||||
| 3-Year FCF Growth Rate | -20.8 | |||||
| 3-Year Book Growth Rate | -30.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 8.37 | |||||
| Future 3-5Y Total Revenue Growth Rate | 23.23 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.02 | |||||
| 9-Day RSI | 38.41 | |||||
| 14-Day RSI | 37.09 | |||||
| 6-1 Month Momentum % | -5.26 | |||||
| 12-1 Month Momentum % | 11.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.83 | |||||
| Quick Ratio | 0.83 | |||||
| Cash Ratio | 0.73 | |||||
| Days Sales Outstanding | 20.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.6 | |||||
| Shareholder Yield % | -39.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -356.01 | |||||
| Net Margin % | -359.18 | |||||
| FCF Margin % | -255.66 | |||||
| ROE % | -108.46 | |||||
| ROA % | -63.84 | |||||
| ROIC % | -90.56 | |||||
| ROC (Joel Greenblatt) % | -198.68 | |||||
| ROCE % | -80.17 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.21 | |||||
| PB Ratio | 2.03 | |||||
| Price-to-Tangible-Book | 2.22 | |||||
| EV-to-EBIT | -1.42 | |||||
| EV-to-EBITDA | -1.63 | |||||
| EV-to-Revenue | 4.88 | |||||
| EV-to-Forward-Revenue | 4.33 | |||||
| EV-to-FCF | -1.91 | |||||
| Price-to-Median-PS-Value | 1.07 | |||||
| Earnings Yield (Greenblatt) % | -70.42 | |||||
| FCF Yield % | -37 | |||||
| Forward Rate of Return (Yacktman) % | -2412.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vaxart Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 18.474 | ||
| EPS (TTM) (€) | -0.377 | ||
| Beta | -0.82 | ||
| Volatility % | 105.65 | ||
| 14-Day RSI | 37.09 | ||
| 14-Day ATR (€) | 0.031057 | ||
| 20-Day SMA (€) | 0.6189 | ||
| 12-1 Month Momentum % | 11.37 | ||
| 52-Week Range (€) | 0.5 - 1.36 | ||
| Shares Outstanding (Mil) | 227.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vaxart Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vaxart Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vaxart Inc Frequently Asked Questions
What is Vaxart Inc(STU:NB11)'s stock price today?
The current price of STU:NB11 is €0.58. The 52 week high of STU:NB11 is €1.36 and 52 week low is €0.50.
When is next earnings date of Vaxart Inc(STU:NB11)?
The next earnings date of Vaxart Inc(STU:NB11) is 2025-03-14 Est..
Does Vaxart Inc(STU:NB11) pay dividends? If so, how much?
Vaxart Inc(STU:NB11) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers